Literature DB >> 10169258

Alternative insurance arrangements and the treatment of depression: what are the facts?

E R Berndt1, R G Frank, T G McGuire.   

Abstract

Using insurance claims data from nine large self-insured employers offering 26 alternative health benefit plans, we examine empirically how the composition and utilization for the treatment of depression vary under alternative organizational forms of insurance (indemnity, preferred provider organization networks, and mental health carve-outs), and variations in patient cost-sharing (copayments for psychotherapy and for prescription drugs). Although total outpatient mental health and substance abuse expenditures per treated individual do not vary significantly across insurance forms, the depressed outpatient is more likely to receive anti-depressant drug medications is preferred provider organizations and carve-outs than when covered by indemnity insurance. Those individuals facing higher copayments for psychotherapy are more likely to receive anti-depressant drug medications. For those receiving treatment, increases in prescription drug copayments tend to increase the share of anti-depressant drug medication costs accounted for by the newest (and more costly) generation of drugs, the selective serotonin reuptake inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10169258

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  5 in total

Review 1.  Mental health policy and psychotropic drugs.

Authors:  Richard G Frank; Rena M Conti; Howard H Goldman
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

2.  Changes in the quality of care for bipolar I disorder during the 1990s.

Authors:  Alisa B Busch; Davina Ling; Richard G Frank; Shelly F Greenfield
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

3.  The impact of parity on major depression treatment quality in the Federal Employees' Health Benefits Program after parity implementation.

Authors:  Alisa B Busch; Haiden A Huskamp; Sharon-Lise T Normand; Alexander S Young; Howard Goldman; Richard G Frank
Journal:  Med Care       Date:  2006-06       Impact factor: 2.983

4.  Changes over time and disparities in schizophrenia treatment quality.

Authors:  Alisa B Busch; Anthony F Lehman; Howard Goldman; Richard G Frank
Journal:  Med Care       Date:  2009-02       Impact factor: 2.983

5.  Does managed care affect the diffusion of psychotropic medications?

Authors:  Marisa E Domino
Journal:  Health Econ       Date:  2011-03-07       Impact factor: 2.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.